Navigation Links
NutraCea Announces Third Quarter 2008 Financial Results

PHOENIX, Nov. 7 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran (SRB) nutrient research and technology, today announced financial results for its third quarter ended September 30, 2008.

Net revenues for the 2008 third quarter increased to $11.2 million compared with net revenues of $1.5 million for the third quarter of 2007. Growth was driven by a $1.9 million increase in net revenues from the Company's NutraCea segment and $7.8 million from its Irgovel subsidiary which was acquired in 2008. Net revenues for the third quarter of 2007 were offset by $1.5 million of returned product.

Sequentially, net revenues for the third quarter of 2008 increased 8.6% over second quarter 2008 net revenues of $10.3 million. The Company's two business segments, NutraCea and Irgovel, recorded net revenues of $3.4 million and $7.8 million, respectively, for third quarter of 2008.

Net loss for the third quarter of 2008 decreased to $4.5 million, or ($0.03) per share, compared to a net loss of $4.8 million or ($0.03) per share, in the comparable period of 2007. The decreased net loss for the 2008 third quarter was primarily due to the increased gross margin of $2.6 million, offset by a net increase of $2.4 million in operating expenses, other expenses and income, and income taxes.

Sequentially, NutraCea realized a reduction in net loss from the $6.1 loss reported in the second quarter of 2008 compared with the $4.5 million net loss reported in the third quarter of 2008. Our NutraCea segment had a loss before income taxes of $5.0 million compared with a net loss before income taxes of $6.9 million in the second quarter of 2008. The Irgovel segment, which was acquired in February 2008, reported income before income taxes of $718,000 for third quarter of 2008.

Sales, General and Administrative (SG&A) expenses totaled $6.5 million for the third quarter of 2008, compared with SG&A expenses of $4.6 million for the third quarter of 2007. The $1.9 million increase was due to $1.2 million of SG&A costs from our Irgovel segment and a $726,000 increase from our NutraCea segment.

Brad Edson, President and CEO of NutraCea commented, "Driven by strong execution of our business model we realized continued improvement in our operations this quarter with results coming in-line with expectations. We are particularly pleased with our consistent sequential sales progress, and sequential improvement reflected in decreased operating costs, reflecting upward repricing, increasing utilization, as well as the improved bottom line performance quarter-over-quarter and sequentially. Results were marked by a strong performance from our recently acquired rice-bran oil manufacturing business unit, Irgovel, which remains on target to achieve the previously forecasted $30 million annualized revenue run rate. Additionally, in support of our expansion strategy, we are aggressively pursuing incremental sales opportunities for our NutraCea core SRB product line and achieved notable growth this period increasing sales by approximately $373,000 in addition to an intentional building of inventory for new customer orders anticipated in the fourth quarter 2008 and first quarter 2009.

Additionally, in a continued effort to enhance our financial position and balance sheet, we recently announced the signing of a proposal letter to obtain a $10.0 million credit facility through Wells Fargo Bank. We also issued $5.0 million of Series D Convertible Preferred Stock to two institutional investors. This financing is expected to provide the resources necessary to complete all projects that we currently have under construction including the planned capacity and technological enhancements at Irgovel".

Leo Gingras, COO, stated, "We remain focused on capitalizing on and extending our success within Irgovel. We are on track to add an additional 45,000 tons of annual capacity at Irgovel by the end of first quarter 2009 which would give us a total annual capacity of 115,000 tons. Based on existing results this would produce a corresponding increase in gross and net revenue of at least 60%. We also anticipate that our proprietary and new patent filed technology will have been installed and operating when this additional capacity comes on line. When fully operational, we believe this could additionally more than double the estimated level of profitability of Irgovel for each quarter going forward. Further, we are moving forward with another planned expansion which is currently estimated to increase the Irgovel annual capacity to over 200,000 tons by the first quarter 2010. "

Nine Month Results

For the first nine months of 2008 the Company's net revenues increased 60% to $26.5 million compared with revenues of $16.5 million for the first nine months of 2007. This $10.0 million increase is attributable to $16.2 million in sales contributed by our Irgovel segment, offset by a $2.7 million decline in product sales and a net decline of $5.0 million of license fee revenues by our NutraCea segment.

The Company's net loss for the first nine months of 2008 totaled $17.4 million, or ($0.12) per share, compared with a net loss of $3.0 million, or ($0.02) per share, in the same period of 2007. The $14.4 million net loss increase for the nine month period was primarily due to the $4.2 million decrease in gross profits, a $6.5 million increase in operating expenses and a $3.7 million net increase in other expenses and income taxes.

Sales, General and Administrative expenses for the first nine months of 2008 were $17.5 million, compared to SG&A expenses of $12.5 million for the first nine months of 2007. This increase is due to a $2.5 million, or 20%, increase in our NutraCea segment to expand investment in personnel, infrastructure, and sales and marketing activities to meet anticipated future demands and $2.5 million of SG&A from our Irgovel subsidiary. SG&A expenses for our Irgovel subsidiary consist of marketing, selling, and administrative expenses.

Brad Edson, President and CEO of NutraCea stated, "We are moving ahead with our China facility and it is anticipated to be over seven times the size of our existing facility in Brazil. This project will incorporate state of the art technology and because of scale is anticipated to generate results that are more than seven times greater than what we are currently achieving in Brazil. This project is progressing and we hope to obtain all the necessary permits and approvals shortly and break ground in the first quarter of 2009.

The Company is closing in on being able to realize some of the benefits of the tremendous amount of effort it has applied towards stabilizing Wheat Bran. We are moving closer to realizing the benefits of these efforts and we believe we are about a year ahead of schedule of deploying this technology into the marketplace. This offers tremendous upside to the company without requiring a corresponding burden of capital. Additionally the Company is finalizing details to further extract incremental value from our Stabilized Rice Bran within the United States with certain initiatives that are now underway. Both of these items will be more fully discussed on the conference call.

"We are proud of the results achieved during the past year and our ability to expand our presence and produce healthy revenue gains. We have built a stronger, more balanced company, and given our global position and recently enhanced financial condition are nicely positioned to leverage the capacity that we have now built. We believe the Company is now close to an inflection point, where our capacity and the ability to utilize it should allow sufficient revenue to be able to be produced to move it into sustained profitability. We continue to proceed into the fourth quarter with expectations for increased top line growth, and continued improvement in bottom line performance. We are optimistic of achieving our goals for the remainder of the year and delivering sequentially improving results, both top line and bottom line, throughout 2009 and beyond."

About NutraCea

NutraCea is a world leader in production and utilization of stabilized rice bran. They hold many patents for stabilized rice bran production technology and proprietary neutraceutical formulas ranging from arthritis, chronic bowel conditions, and effective diabetes control to cardiovascular disease treatment protocols. NutraCea's proprietary technology enables the creation of food and nutrition products to be unlocked from rice bran, normally a waste by-product of standard rice processing. Committed to helping the underfed, they're heavily involved in providing product and technology for developing countries through NutraCea's RiceAde feeding program. More information can be found in the Company's filings with the SEC, and you can visit the NutraCea Web site

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding the likelihood that the bank will proceed with the completion of the credit facility as described in the proposal letter, or that it will proceed with any credit facility, the ability of NutraCea to comply with the conditions set forth in the loan proposal or that the bank will extend credit, even if such conditions are met, and the availability of any funds pursuant to that facility, due to the non-binding nature of the loan proposal, our expectations that the Series D Preferred Stock financing will provide the resources necessary to complete all projects currently under construction, the ability of Irgovel to remain on target to achieve forecasted revenue, the timing and cost of completion of projects under construction and the increased capacity resulting from the completion of those projects, the anticipated capacity and the progress and timing of receipt of permits and start of construction of the China facility, our belief regarding the deployment of our Stabilized Wheat Bran technology about one year ahead of schedule and the upside of our Stabilized Wheat Bran technology, our belief that we are close to an inflection point, where our capacity and the ability to utilize it should allow sufficient revenue to be able to be produced to move NutraCea into sustained profitability, and our expectations for increased top line growth and continued improvement in bottom line performance. Actual results may differ from those projected, due to a number of risks and uncertainties, including, but not limited to, the matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the Company's most recent periodic report.



September 30, December 31,

2008 2007

ASSETS (Unaudited)

Current assets:

Cash and cash equivalents $8,702,000 $41,298,000

Restricted cash 2,363,000 758,000

Trade accounts receivable,

net of allowance for doubtful

accounts of $3,404,000 and

$2,999,000, respectively 2,992,000 2,346,000

Inventories 4,945,000 1,808,000

Notes receivable, net of

allowance for doubtful notes

receivable of $573,000 and

$250,000, respectively 921,000 2,936,000

Deposits and other current

assets 3,248,000 2,545,000

Total current assets 23,171,000 51,691,000

Restricted cash 1,344,000 1,791,000

Notes receivable, net of

current portion - 5,039,000

Property and equipment, net 46,652,000 19,328,000

Investment in joint ventures 11,751,000 1,191,000

Patents and trademarks, net

of accumulated amortization 5,139,000 5,743,000

Other non-current 124,000 -

Goodwill, net of $1,300,000

impairment 52,668,000 39,510,000

Total assets $140,849,000 $124,293,000



Current liabilities:

Accounts payable and accrued

liabilities $15,126,000 $7,596,000

Notes payable, current portion 710,000 23,000

Total current liabilities 15,836,000 7,619,000

Long-term liabilities:

Notes payable, net of current

portion 4,379,000 77,000

Total liabilities 20,215,000 7,696,000

Commitments and contingencies - -

Shareholders' equity:

Common stock, no par value,

350,000,000 shares authorized,

167,994,000 and 144,108,000

shares issued and outstanding 199,185,000 177,813,000

Accumulated deficit (78,594,000) (61,216,000)

Foreign currency cumulative

translation adjustment 43,000 -

Total shareholders' equity 120,634,000 116,597,000

Total liabilities and

shareholder's equity $140,849,000 $124,293,000




Three Months Three Months Nine Months Nine Months

Ended Ended Ended Ended

September 30, September 30, September 30, September 30,

2008 2007 2008 2007


Product sales, net

discounts $11,193,000 $3,048,000 $26,563,000 $13,031,000

Less sales

returns - (1,551,000) (119,000) (1,551,000)

Licensing and

royalty revenue 8,000 23,000 39,000 5,033,000

Total revenues 11,201,000 1,520,000 26,483,000 16,513,000

Cost of sales 8,704,000 1,635,000 20,775,000 6,611,000

Gross profit (loss) 2,497,000 (115,000) 5,708,000 9,902,000

Operating expenses

Research and


expenses 266,000 155,000 1,268,000 446,000

Selling, general

and administrative

expenses 6,484,000 4,576,000 17,534,000 12,546,000

Professional fees 303,000 747,000 3,385,000 2,742,000

Total operating

expenses 7,053,000 5,478,000 22,187,000 15,734,000

(Loss) from

operations (4,556,000) (5,593,000) (16,479,000) (5,832,000)

Other income


Interest income 176,000 778,000 597,000 2,167,000

Interest expense (107,000) - (448,000) -

Gain on settlement - - - 1,250,000

Gain (loss) on

disposal of assets 211,000 - (462,000) (309,000)

Loss on equity

investments (35,000) (36,000) (115,000) (286,000)

Total loss before

income tax (4,311,000) (4,851,000) (16,907,000) (3,010,000)

Income tax expense (222,000) 67,000 (541,000) (18,000)

Net loss from


operations (4,533,000) (4,784,000) (17,448,000) (3,028,000)

Minority interest - - 70,000 -

Net loss $(4,533,000) $(4,784,000) $(17,378,000) $(3,028,000)

Basic and diluted

loss per share:

Basic loss per

share $(0.03) $(0.03) $(0.12) $(0.02)

Fully diluted

loss per share $(0.03) $(0.03) $(0.12) $(0.02)

Weighted average basic

number of shares

outstanding 167,866,000 141,084,000 147,947,000 131,054,000

Weighted average

diluted number

of shares

outstanding 167,866,000 141,084,000 147,947,000 131,054,000

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NutraCea Announces Third Quarter 2008 Conference Call
2. Mike Bridges Takes Home Four Gold Medals at IPF Masters World Powerlifting Championships; Says NutraCeas RiSolubles(R) is an Essential Part of his Training Regimen
3. U.S. Chamber Recognizes NutraCea for Strong Corporate Stewardship
4. NutraCea Announces First Quarter 2008 Financial Results
5. NutraCea to Host First Quarter 2008 Conference Call on May 12.
6. NutraCea Announces $20 Million Securities Offering
7. Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule
8. NutraCea-Sponsored Study Demonstrates Benefits of Replacing Wheat Flour with Stabilized Rice Bran (SRB) in Battered and Fried Product Applications
9. NutraCea Appoints New Chief Financial Officer
10. New World Record Holder in Powerlifting Credits NutraCeas Unique Rice-Bran-derived Product as his Secret Weapon
11. NutraCea to Purchase Largest Rice Bran Oil Processing Facility in South America
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
Breaking Medicine Technology: